Cargando…
Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes
BACKGROUND: PRAME (preferentially expressed antigen in melanoma), a member of the cancer-testis antigen family, has been shown to have increased expression in solid tumors, including sarcoma, and PRAME-specific therapies are currently in development for other cancers such as melanoma. METHODS: To ma...
Autores principales: | Roszik, Jason, Wang, Wei-Lien, Livingston, John A., Roland, Christina L., Ravi, Vinod, Yee, Cassian, Hwu, Patrick, Futreal, Andrew, Lazar, Alexander J., Patel, Shreyaskumar R., Conley, Anthony P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471883/ https://www.ncbi.nlm.nih.gov/pubmed/28630682 http://dx.doi.org/10.1186/s13569-017-0077-3 |
Ejemplares similares
-
MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma
por: Conley, Anthony P., et al.
Publicado: (2019) -
Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma
por: Albertsmeier, Markus, et al.
Publicado: (2020) -
Positive Tumor Response to Combined Checkpoint Inhibitors in a
Patient With Refractory Alveolar Soft Part Sarcoma: A Case
Report
por: Conley, Anthony P., et al.
Publicado: (2017) -
Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets
por: Roszik, Jason, et al.
Publicado: (2019) -
PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy
por: Luk, Sietse J, et al.
Publicado: (2018)